|
Report Date : |
10.12.2014 |
IDENTIFICATION DETAILS
|
Name : |
SANDOZ GMBH |
|
|
|
|
Formerly Known As : |
BIOCHEMIE GMBH |
|
|
|
|
Registered Office : |
Biochemiestraße 10, A-6250 Kundl |
|
|
|
|
Country : |
Austria |
|
|
|
|
Financials (as on) : |
31.12.2013 |
|
|
|
|
Year of Establishment : |
1965 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacture of Pharmaceutical Preparations. |
|
|
|
|
No. of Employees : |
3628 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
Austria |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
AUSTRIA - ECONOMIC
OVERVIEW
Austria, with its
well-developed market economy, skilled labor force, and high standard of living,
is closely tied to other EU economies, especially Germany's. Its economy
features a large service sector, a sound industrial sector, and a small, but
highly developed agricultural sector. Following several years of solid foreign
demand for Austrian exports and record employment growth, the international Financial crisis
of 2008 and subsequent global economic downturn led to a sharp but brief
recession. Austrian GDP contracted 3.8% in 2009 but saw positive growth of
about 2% in 2010 and 2.7% in 2011. Growth fell to 0.6% in 2012. Unemployment
did not rise as steeply in Austria as elsewhere in Europe, partly because the
government subsidized reduced working hour schemes to allow companies to retain
employees. The 2012 unemployment rate of 4.3% was the lowest within the EU.
Stabilization measures, stimulus spending, and an income tax reform pushed the
budget deficit to 4.5% in 2010 and 2.6% in 2011, from only about 0.9% in 2008.
The international financial crisis of 2008 caused difficulties for Austria's largest
banks whose extensive operations in central, eastern, and southeastern Europe
faced large losses. The government provided bank support - including in some
instances, nationalization - to support aggregate demand and stabilize the
banking system. Austria's fiscal position compares favorably with other
euro-zone countries, but it faces external risks, such as Austrian banks'
continued exposure to Central and Eastern Europe as well as political and
economic uncertainties caused by the European sovereign debt crisis. In 2011
the government attempted to pass a constitutional amendment limiting public
debt to 60% of GDP by 2020, but it was unable to obtain sufficient support in
parliament and instead passed the measure as a simple law. In March 2012, the Austrian
parliament approved an austerity package consisting of a mix of expenditure
cuts and new revenues that will bring public finances into balance by 2016. In
2012, the budget deficit rose to 3.1% of GDP.
|
Source
: CIA |
|
Company name: |
Sandoz GmbH |
|
Status: |
active company |
|
Locations: |
Biochemiestraße 10, A-6250 Kundl |
|
Phone: |
0043 (5338) 200 |
|
Fax: |
0043 (5338) 200 - 415 |
|
E-mail: |
|
|
Internet: |
|
|
Internet: |
|
|
Activities: |
Önace 21200 100% Manufacture of pharmaceutical
preparations |
|
|
|
|
Detail Assessment: |
Payments are made within net agreements. |
|
|
Financial situation is good. |
|
Date
of collection order |
Amount presently due |
Amount presently paid |
Collection status quo |
since |
|
2013-05-16 |
EUR 0,00 |
EUR 578,31 |
Payment after debt collection |
2013-06-17 |
|
2012-11-08 |
EUR 0,00 |
EUR 348,96 |
Payment after debt collection |
2012-12-04 |
|
Sums |
EUR 0,00 |
EUR 927,27 |
|
|
|
Year of incorporation: |
1965 |
|
||||
|
Activities: |
-- |
|
||||
|
Type of company: |
Manufacturing |
|
||||
|
Legal form: |
limited liability company since 1965-11-18 |
|
||||
|
companies' house number: |
FN 50587 v Innsbruck 1965-11-26 |
|
||||
|
VAT number: |
ATU 32425809 |
|
||||
|
ARA-number: |
3462 |
|
||||
|
number - Austrian National Bank: |
4812 |
|
||||
|
|
||||||
|
Export |
Country |
|
|
|
||
|
Export |
world-wide |
|
2014 |
|
||
|
total turnover (total sales) |
2013 |
EUR 1.496.118.876,88 |
(exact) |
|
total turnover (total sales) |
2012 |
EUR 1.449.492.227,45 |
(exact) |
|
total turnover (total sales) |
2011 |
EUR 1.480.566.195,12 |
(exact) |
|
total turnover (total sales) |
2010 |
EUR 1.428.954.760,56 |
(exact) |
|
total turnover (total sales) |
2009 |
EUR 1.315.733.905,62 |
(exact) |
|
total employees |
2014 |
3628 |
(approx.) |
|
total investments |
2013 |
EUR 159.715.369,74 |
(exact) |
|
firm
(style): |
|
63
Sandoz GmbH |
|
legal
form: |
|
1
Gesellschaft mit beschränkter Haftung |
|
registered
office: |
|
1
politischer Gemeinde Kundl |
|
business
adress: |
|
15
Biochemiestraße 10 |
|
capital: |
|
52
EUR 32.703.000 |
|
reference
date annual accounts: |
|
1
31. Dezember |
|
annual
accounts: |
|
139
zum 31.12.2013 eingereicht am 11.09.2014 |
|
power
of representation: |
|
1
Die Gesellschaft wird, wenn mehrere Geschäftsführer |
|
other
provisions: |
|
8
Der Aufsichtsrat besteht aus sechs Mitgliedern. |
|
proxy: |
|
CT
Sibylla Härtel, geb. 21.10.1962 |
|
supervisory
board: |
|
CX
Helmut Pancheri, geb. 05.07.1961 |
|
managing
director: |
|
BD
Mag. Hubert Hirzinger, geb. 10.05.1957 |
|
shareholder: |
|
CM
Novartis Holding AG |
|
general
table: |
|
Landesgericht Innsbruck |
|
Registration number of real estate 100
Cadastral register 83108 Kundl T Number and date of
entry 2460/2011 Status of 2013-10-11 |
|
Part
A - type of real estate : |
|
GST-NR
G BA (NUTZUNG)
FLÄCHE GST-ADRESSE |
|
Part
B - ownership details : |
|
1 ANTEIL: 1/1 |
|
Part
C - registered charges : |
|
3
a 1589/1993 |
|
Surname |
Date of birth |
Address |
Executive positions |
Further executive positions
(as registered in the companies' house) |
|
Mag. Hubert Hirzinger |
1957-05-10 |
6250 Kundl Biochemiestraße 10
(p/A Sandoz GmbH) |
manager |
4 |
|
Dipl-Ing. Ernst
Meijinders |
1956-12-14 |
6250 Kundl Biochemiestraße 10 |
manager |
0 |
|
Dkfm. Klaus Neumayer |
1964-07-17 |
6250 Kundl Biochemiestraße 10 |
manager |
0 |
|
Dr. Thomas Nothegger |
1967-07-11 |
6250 Kundl c/o Sandoz GmbH
Biochemiestraß 10 |
manager |
0 |
|
Dr. Jens Scheibner |
1968-11-15 |
6250 Kundl c/o Sandoz GmbH
Biochemiestraß 10 |
manager |
0 |
|
Mag. Hans Peter Amon |
1975-01-19 |
1020 Wien Stella Klein Löwweg
17 |
joint signing clerk, head of accounting |
4 |
|
Dkfm. Michael Friedhofen |
1967-08-27 |
1020 Wien Stella Klein Löwweg
17 |
joint signing clerk |
1 |
|
Sibylla Härtel |
1962-10-21 |
6250 Kundl Biochemiestraße
10(c/o) |
joint signing clerk |
0 |
|
Dip.-Chem. Michael
Kocher |
1967-04-12 |
6250 Kundl c/o Sandoz GmbH
Biochemiestraß 10 |
joint signing clerk |
0 |
|
Dr. Nikolaus Kofler |
1968-12-05 |
6250 Kundl c/o Sandoz GmbH
Biochemiestraß 10 |
joint signing clerk |
0 |
|
Dr. Christopher Manuel
Mader |
1973-04-10 |
6250 Kundl c/o Sandoz GmbH
Biochemiestraß 10 |
joint signing clerk |
0 |
|
Rodrigo Goarmon Pedroso
Santos-Ferreira |
1978-11-10 |
1020 Wien Stella Klein Löwweg
17 |
joint signing clerk |
2 |
|
|
Ferreira |
|||
|
Mag. Ingrid
Schwarzenberger |
1958-03-20 |
6250 Kundl Biochemiestraße
10(c/o) |
joint signing clerk |
0 |
|
Dr. Josef Egerbacher |
1958-11-20 |
6250 Kundl Biochemiestraße
10(c/o) |
chairman of the supervisory
board, member of the supervisory
board |
0 |
|
Dr. Andreas Brutsche |
1962-09-17 |
83607 Holzkirchen
Industriestraße 25 |
deputy chairman of the supervisory
board |
0 |
|
Barbara Nerad |
1962-12-30 |
6250 Kundl Biochemiestraße 10 |
member of the supervisory
board |
0 |
|
Helmut Pancheri |
1961-07-05 |
6250 Kundl Biochemiestraße
10(c/o) |
member of the supervisory
board |
0 |
|
Sandrine Charlotte Philippe
Piret-Gerard |
1975-10-17 |
83607 Holzkirchen c/o HEXAL AG
Industriestraße 25 |
member of the supervisory
board |
0 |
|
Felix Senn |
1959-05-26 |
4056 Basel Novartis Campus
Forum 1 |
member of the supervisory
board |
0 |
|
Mag. Max Leitinger |
|
6250 Kundl Biochemiestraße
10(c/o) |
head of EDP |
0 |
|
Josef Postl |
|
6250 Kundl Biochemiestraße
10(c/o) |
technical director |
0 |
|
|
2013-12-31 |
|
|
|
|
|
Franchises, patents, licences, trademarks and similar
rights and advantages |
10.517.586,87 |
|
|
|
|
|
Sum intangible assets |
10.517.586,87 |
|
|
|
|
|
|
|||||
|
Land and leasehold rights with buildings thereon including
building on land owned by third parties |
272.157.348,76 |
|
|
|
|
|
Other operating and business equipment |
19.349.235,85 |
|
|
|
|
|
Technical plants and machines |
147.003.610,97 |
|
|
|
|
|
Advanced payments and constructions in progress |
85.077.459,40 |
|
|
|
|
|
Sum tangible assets |
523.587.654,98 |
|
|
|
|
|
|
|||||
|
Shares on related firms |
56.831.602,18 |
|
|
|
|
|
Other shareholdings |
1.751.901,77 |
|
|
|
|
|
Other financial assets, values and securities of fixed
assets |
18.051.774,04 |
|
|
|
|
|
Sum financial assets |
76.635.277,99 |
|
|
|
|
|
|
|||||
|
Sum fixed assets |
610.740.519,84 |
|
|
|
|
|
|
|||||
|
Raw-, auxiliary materials and supplies |
80.531.973,71 |
|
|
|
|
|
Unfinished products |
154.198.842,07 |
|
|
|
|
|
Finished products |
37.655.853,59 |
|
|
|
|
|
Sum stock |
272.386.669,37 |
|
|
|
|
|
|
|||||
|
Claims from delivered goods and performed services |
130.329.080,94 |
|
|
|
|
|
Claims against related firmes Claims against companies
with shareholding relationship |
141.547.017,72 |
|
|
|
|
|
Other claims and assets |
54.046.409,90 |
|
|
|
|
|
Sum claims |
325.922.508,56 |
|
|
|
|
|
|
|||||
|
Cash on hand, cheques and bank deposits |
4.781.773,95 |
|
|
|
|
|
Sum cash and bank |
4.781.773,95 |
|
|
|
|
|
|
|||||
|
Sum current assets |
603.090.951,88 |
|
|
|
|
|
|
|||||
|
Deferred charges |
949.397,27 |
|
|
|
|
|
Sum deferred charges |
949.397,27 |
|
|
|
|
|
Assets |
1.214.780.868,99 |
|
|
|
|
|
|
|||||
|
Subscribed/declared capital |
32.703.000,00 |
|
|
|
|
|
Legal reserves |
3.270.300,00 |
|
|
|
|
|
Free reserves |
99.991.891,44 |
|
|
|
|
|
Balance sheet profit/balance sheet loss |
0,00 |
|
|
|
|
|
Sum equity capital |
135.965.191,44 |
|
|
|
|
|
|
|||||
|
Other reserves before taxes |
24.061.760,15 |
|
|
|
|
|
Sum reserves before taxes |
24.061.760,15 |
|
|
|
|
|
|
|||||
|
Investment contributions |
557.404,46 |
|
|
|
|
|
Sum floor capital |
557.404,46 |
|
|
|
|
|
|
|||||
|
Reserves for severance pays |
47.244.982,00 |
|
|
|
|
|
Reserves for pensions |
62.223.887,00 |
|
|
|
|
|
Other reserves |
75.068.795,26 |
|
|
|
|
|
Sum reserves |
184.537.664,26 |
|
|
|
|
|
|
|||||
|
Liabilities against credit institutes |
4.416.356,48 |
|
|
|
|
|
Received advanced payments for orders |
6.711.020,99 |
|
|
|
|
|
Liabilities from delivered goods and performed services |
121.144.856,15 |
|
|
|
|
|
Liabilities against related firms |
718.491.287,70 |
|
|
|
|
|
Liabilities against firm with shareholding relationship |
2.476.066,96 |
|
|
|
|
|
Other liabilities |
7.970.213,28 |
|
|
|
|
|
Other loans |
1.474.413,00 |
|
|
|
|
|
Sum liabilities |
862.684.214,56 |
|
|
|
|
|
|
|||||
|
Deferred income |
6.974.634,12 |
|
|
|
|
|
Sum deferred income |
6.974.634,12 |
|
|
|
|
|
Liabilities |
1.214.780.868,99 |
|
|
|
|
|
|
|||||
|
Contingent liabilities |
1.700.000,00 |
|
|
|
|
|
Balance sheet sum |
1.214.780.868,99 |
|
|
|
|
|
|
2013-12-31 |
|
|
|
|
|
Gross sales |
1.496.118.876,88 |
|
|
|
|
|
Increase or decrease in finished and unfinished goods and
in service claims |
-3.688.594,78 |
|
|
|
|
|
Other manufacturing costs capitalized |
4.943.709,32 |
|
|
|
|
|
Total turnover or gross profit |
1.497.373.991,42 |
|
|
|
|
|
|
|||||
|
Profits from retirement of fixed assets, except financial
assets |
52.284,01 |
|
|
|
|
|
Other operating profits |
25.610.882,10 |
|
|
|
|
|
Other operating profits totally |
25.663.166,11 |
|
|
|
|
|
|
|||||
|
Costs for obtained services |
-35.905.614,21 |
|
|
|
|
|
Material costs |
-812.029.603,51 |
|
|
|
|
|
Costs for obtained services totally |
-847.935.217,72 |
|
|
|
|
|
|
|||||
|
Wages |
-27.252.938,16 |
|
|
|
|
|
Salaries |
-159.084.034,37 |
|
|
|
|
|
Costs for severance pays |
-3.639.921,46 |
|
|
|
|
|
Costs for old age pension |
-6.652.421,94 |
|
|
|
|
|
Legal fringe benefits and other payments depending on
salaries |
-48.815.704,62 |
|
|
|
|
|
Other social fringe benefits |
-6.969.046,50 |
|
|
|
|
|
Personnel expenses totally |
-252.414.067,05 |
|
|
|
|
|
|
|||||
|
Depreciation of intangible assets, tangible
assets,activated expenses for the set up and expansion of business
operation |
-67.475.792,73 |
|
|
|
|
|
Depreciation tangible assets / intangible assets
totally |
-67.475.792,73 |
|
|
|
|
|
|
|||||
|
Other operating costs |
-314.828.351,82 |
|
|
|
|
|
Other taxes |
-582.752,31 |
|
|
|
|
|
Total costs |
-315.411.104,13 |
|
|
|
|
|
|
|||||
|
Operating result totally |
39.800.975,90 |
|
|
|
|
|
|
|||||
|
Profits from shareholdings |
11.027.987,22 |
|
|
|
|
|
Income from other securities and loans of financial
assets |
551.302,92 |
|
|
|
|
|
Interest income, securties income and similar income |
99,97 |
|
|
|
|
|
Interest and similar disbursements |
-11.860.973,78 |
|
|
|
|
|
Financial profits totally |
-281.583,67 |
|
|
|
|
|
|
|||||
|
Results from usual business activity
totally |
39.519.392,23 |
|
|
|
|
|
|
|||||
|
Taxes on income and profits |
-8.044,52 |
|
|
|
|
|
Taxes on income and profits totally |
-8.044,52 |
|
|
|
|
|
Annual surplus/annual deficit
totally |
39.511.347,71 |
|
|
|
|
|
|
|||||
|
Dissolution reserves before taxes |
824.117,96 |
|
|
|
|
|
Transfer to profit reserves |
-40.335.465,67 |
|
|
|
|
|
Reserves movements totally |
-39.511.347,71 |
|
|
|
|
|
B/S profit/ B/S loss from profit and
loss account |
0,00 |
|
|
|
|
|
|
2013 |
|
|
|
|
|
|
Cash flow II |
106.987.140,44 |
|
|
|
|
|
|
Debt amortisation period |
9,68 |
|
|
|
|
|
|
Bank indebtedness |
0,48 |
|
|
|
|
|
|
Equity capital share |
13,29 |
|
|
|
|
|
|
Social capital share |
9,01 |
|
|
|
|
|
|
Fixed assets coverage |
44,21 |
|
|
|
|
|
|
Net profit ratio |
2,63 |
|
|
|
|
|
|
Capital turnover |
1,23 |
|
|
|
|
|
|
Return on investment |
4,22 |
|
|
|
|
|
|
Cash flow in % of operating performance |
7,14 |
|
|
|
|
|
|
Cash flow I |
106.995.184,96 |
|
|
|
|
|
|
Gross productivity |
5,93 |
|
|
|
|
|
|
Net productivity |
2,57 |
|
|
|
|
|
|
Operating performance |
1.497.373.991,42 |
|
|
|
|
|
|
Inventories in % of operating performance |
18,19 |
|
|
|
|
|
|
Gross profit |
649.438.773,70 |
|
|
|
|
|
|
Type |
Locations |
Description |
|
|
|
E-mail |
|
operational |
Biochemiestraße 10, A-6250 Kundl |
registered office |
|
|
|
|
|
operational |
Biochemiestraße 10, A-6250 Kundl |
registered headquarters, owned property |
|
|
|
kundl.austria@sandoz.com |
|
operational |
Brunnerstraße 59, A-1230 Wien |
branch office, rented premises |
|
|
|
|
|
operational |
Schaftenau Biochemiestraße 10, A-6330 Kufstein |
factory, owned property |
|
|
|
|
|
operational |
Dr. Hans Bachmannstraße 7, A-6250 Kundl, (umben.auf
Biochemiestraße 10) |
registered headquarters |
|
|
|
|
|
former |
Wagramerstraße 19, A-1220 Wien |
branch office |
|
Company name |
Postal code |
Stake in % |
|
Companies House |
|
Shares in this company are
held by: |
||||
|
Novartis Austria GmbH |
Stella Klein Löwweg 17, A-1020 Wien |
99.99 % 2006-07-27 |
|
FN 274620 d |
|
Novartis Holding AG |
Lichtstraße 35, CH-4056 Basel |
0.01 % 1997-02-22 |
|
|
|
|
||||
|
This company holds 100% of the
shares in: |
||||
|
HEXAL PHARMA GmbH |
Stella Klein Löwweg 17, A-1020 Wien |
100 % 2005-12-17 |
|
FN 44896 z |
|
Novartis Institutes for Biomedical Research GmbH |
Biochemiestraße 10, A-6250 Kundl |
100 % 1993-08-13 |
|
FN 43251 f |
|
|
||||
|
Affiliated companies and
further participations: |
||||
|
HBHG Pharma Ges.m.b.H. |
Mondseestraße 11, A-4866 Unterach Attersee |
|
|
FN 215663 b |
|
Novartis Pharma GmbH |
Stella Klein Löwweg 17, A-1020 Wien |
|
|
FN 41622 i |
|
EBEWE Spezial-Pharma Holding GmbH |
Stella Klein Löwweg 17, A-1020 Wien |
|
|
FN 331193 z |
|
Novartis Institutes for BioMedical Research GmbH & Co
KG |
Brunnerstraße 59, A-1235 Wien |
2004-10-23 |
|
FN 253505 b |
|
Austrian Center of Biopharmaceutical Technology |
Muthgasse 18, A-1190 Wien |
|
|
|
|
Nabriva Therapeutics AG |
Leberstraße 20, A-1112 Wien |
|
|
FN 269261 y |
|
Banker |
Bank sort code |
Type of banking connection |
|
UniCredit Bank Austria AG, 1011 Wien |
12000 |
main bank connection |
|
Year of incorporation: |
1965 |
|
Date of registration: |
1965-11-26 |
|
Change of company name: |
||
|
From |
To |
Company name |
|
|
2003-05-02 |
Biochemie GmbH |
|
2003-05-02 |
|
Sandoz GmbH |
|
Change in share capital: |
||
|
From |
To |
Capital |
|
|
2001-10-05 |
ATS 450.000.000,00 |
|
2001-10-05 |
|
EUR 32.703.000,00 |
|
Former executives: |
|||
|
From |
To |
Function |
Name |
|
|
1999-04-13 |
manager |
Dipl-Ing.Dr. Oswald Sellemond |
|
|
2003-04-29 |
manager |
Werner Meßner |
|
2003-04-29 |
2004-09-01 |
manager |
Mag.Dr. Franz Stumpf |
|
2003-04-29 |
2005-07-28 |
manager |
Mag. Hubert Hirzinger |
|
2003-04-29 |
2005-07-28 |
manager |
Dr. Patrick Vink |
|
|
2006-06-03 |
manager |
Dipl-Ing.Dr. Heinrich Scherfler |
|
1998-10-20 |
1999-04-15 |
joint signing clerk |
Eric Gorka |
|
1999-04-15 |
2003-03-19 |
joint signing clerk |
Mag. Gerhard Hörl |
|
1999-08-17 |
2003-04-29 |
joint signing clerk |
Mag.Dr. Franz Stumpf |
|
1993-09-23 |
2000-10-11 |
joint signing clerk |
Mag. Hubert Hirzinger |
|
1993-09-23 |
2001-10-02 |
joint signing clerk |
Dr. Walter Killiches |
|
2006-06-23 |
2007-06-15 |
joint signing clerk |
Lorraine Lynne Christina Perry |
|
2000-01-12 |
2010-01-09 |
joint signing clerk |
Dr. Josef Egerbacher |
|
1999-10-12 |
2001-10-02 |
chairman of the supervisory board |
Dipl-Ing.Dr. Oswald Sellemond |
|
2001-10-02 |
2002-05-30 |
chairman of the supervisory board |
Mag. Christian Seiwald |
|
2002-05-30 |
2005-04-19 |
chairman of the supervisory board |
Mag. Christian Seiwald |
|
2010-07-29 |
2013-10-05 |
chairman of the supervisory board |
Mag. Christian Seiwald |
|
2005-04-19 |
2010-07-29 |
deputy chairman of the supervisory board |
Mag. Christian Seiwald |
|
|
2014-07-16 |
deputy chairman of the supervisory board |
Dr. Josef Egerbacher |
|
1999-08-06 |
1999-10-12 |
member of the supervisory board |
Dipl-Ing.Dr. Oswald Sellemond |
|
1999-08-06 |
2001-10-02 |
member of the supervisory board |
Mag. Christian Seiwald |
|
2001-10-02 |
2002-05-30 |
member of the supervisory board |
Dipl-Ing.Dr. Oswald Sellemond |
|
2007-03-16 |
2011-06-30 |
member of the supervisory board |
Dipl-Ing.Dr. Heinrich Scherfler |
|
|
2013-10-05 |
member of the supervisory board |
Dr. Josef Egerbacher |
|
|
2014-07-16 |
member of the supervisory board |
Dr. Andreas Brutsche |
|
|
2013-10-05 |
deputy chairman of the
supervisory board |
Peter Goldschmidt |
|
2003-04-29 |
2008-02-21 |
manager |
Mag. Bernhard Sigl |
|
2010-11-13 |
2012-12-18 |
manager |
Mag. Richard Kronbichler |
|
2010-02-20 |
2014-01-22 |
manager |
Dr. Peter Gasteiger |
|
2010-01-09 |
2014-05-15 |
manager |
Dr. Günter Stempfer |
|
1993-09-23 |
1999-02-16 |
joint signing clerk |
Dr. Paul Inama Sternegg |
|
1993-09-23 |
2000-09-13 |
joint signing clerk |
Dr. Otto Streichsbier |
|
1998-01-27 |
2002-04-25 |
joint signing clerk |
Mag. Vinzenz Plörer |
|
1997-11-07 |
2002-10-01 |
joint signing clerk |
Dr. Helmut Deimel |
|
1993-09-23 |
2003-04-29 |
joint signing clerk |
Mag. Bernhard Sigl |
|
2001-10-02 |
2003-12-18 |
joint signing clerk |
MMag.Dr. Johannes
Gerstenbauer |
|
1998-01-27 |
2003-12-18 |
joint signing clerk |
Mag. Gottfried Rieser |
|
1993-09-23 |
2005-03-08 |
joint signing clerk |
Dr. Ernst Leitner |
|
1998-02-02 |
2005-03-08 |
joint signing clerk |
Peter Haselböck |
|
1993-09-23 |
2001-03-13 |
joint signing clerk |
Dr. Eberhard Pirich |
|
1998-01-27 |
2006-05-16 |
joint signing clerk |
Dr. Santiago Alonso
Ciriza |
|
2004-08-10 |
2006-05-16 |
joint signing clerk |
Knut Ulrich Mager |
|
2000-03-14 |
2006-05-16 |
joint signing clerk |
Hans Schaller |
|
1993-09-23 |
2007-02-09 |
joint signing clerk |
Mag. Rupert Labner |
|
2003-10-01 |
2007-06-15 |
joint signing clerk |
Mag.Dr. Otto Scheidl |
|
2002-07-17 |
2007-06-15 |
joint signing clerk |
Dr. Elisabeth Schneider
Scherzer |
|
2000-01-12 |
2007-06-15 |
joint signing clerk |
Mag. Barbara Weigl Aman |
|
1998-04-02 |
2007-06-15 |
joint signing clerk |
Dr. Bruno Wallnöfer |
|
2004-10-06 |
2008-05-29 |
joint signing clerk |
MBA. Elgar Schnegg |
|
2000-05-31 |
2009-02-19 |
joint signing clerk |
Kurt Unterkircher |
|
1993-09-23 |
2010-03-19 |
joint signing clerk |
Mag. Friedrich Fuchs |
|
2006-06-23 |
2011-02-10 |
joint signing clerk |
Mag. Helmuth Hofer |
|
2001-12-19 |
2012-05-01 |
joint signing clerk |
Dr. Maria Schmalzl |
|
1998-01-27 |
2012-10-17 |
joint signing clerk |
Dr. Elmar Dolejsi |
|
|
2014-03-18 |
joint signing clerk |
Dr. Friedrich Sernetz |
|
1993-05-10 |
1997-05-16 |
chairman of the supervisory
board |
Dr. Urs Bärlocher |
|
2002-03-12 |
2005-07-14 |
member of the supervisory
board |
Dr. Urs Bärlocher |
|
1997-05-16 |
1998-04-18 |
chairman of the supervisory
board |
Pierre Douaze |
|
1998-04-18 |
1999-10-12 |
chairman of the supervisory
board |
Dr. Argeric Karabelas |
|
1999-10-12 |
2000-11-30 |
deputy chairman of the supervisory
board |
Dr. Argeric Karabelas |
|
2005-04-19 |
2009-02-19 |
chairman of the supervisory
board |
Dr. Andreas Rummelt |
|
2009-03-11 |
2010-04-20 |
member of the supervisory
board |
Dr. Andreas Rummelt |
|
1997-05-16 |
2002-03-12 |
deputy chairman of the
supervisory board |
Dr. Jörg Reinhardt |
|
2000-11-30 |
2002-05-30 |
deputy chairman of the
supervisory board |
Thomas Ebeling |
|
2002-05-30 |
2005-04-19 |
deputy chairman of the
supervisory board |
Paul Choffat |
|
2010-07-29 |
2012-09-26 |
deputy chairman of the
supervisory board |
Christina Ackermann
Swistara |
|
2010-04-20 |
2010-07-29 |
member of the supervisory
board |
Christina Ackermann
Swistara |
|
|
1998-04-18 |
member of the supervisory
board |
Daniel Wagniere |
|
1998-04-18 |
1999-08-06 |
member of the supervisory
board |
Dr. Hans Kindler |
|
1997-05-16 |
1999-08-06 |
member of the supervisory
board |
Dr. Erwin Schillinger |
|
2002-05-30 |
2007-06-28 |
member of the supervisory board |
Dr. Erwin Schillinger |
|
2005-07-14 |
2007-03-16 |
member of the supervisory
board |
Kevin Plummer |
|
1999-08-06 |
2008-08-01 |
member of the supervisory
board |
Hermann Egger |
|
2007-06-28 |
2008-08-01 |
member of the supervisory
board |
Dr. Peter Jager |
|
2008-08-01 |
2009-03-11 |
member of the supervisory
board |
Knut Mager |
|
2010-09-22 |
2012-03-09 |
member of the supervisory
board |
Dr. Gerhard Schaefer |
|
|
1998-01-24 |
employee's representative on the
supervisory board |
Johann Auer |
|
|
1999-08-06 |
employee's representative on
the supervisory board |
Helmuth Stubenvoll |
|
2004-09-01 |
2007-06-06 |
manager |
Mag. Johannes Schwertner |
|
2010-01-09 |
2012-02-03 |
manager |
Mag. Hannes Teißl |
|
|
2014-07-16 |
chairman of the supervisory
board |
Hans Helmut Michael
Fabry |
|
2011-06-30 |
2013-10-05 |
member of the supervisory
board |
Hans Helmut Michael
Fabry |
|
|
1997-05-16 |
member of the supervisory board |
Dr. Raymund Breu |
|
2008-02-21 |
2010-02-20 |
manager |
Dipl-Ing. Bianca Stöhr |
|
2003-05-06 |
2004-11-03 |
joint signing clerk |
Mag. Siegfried Johann
Leitner |
|
2008-05-29 |
2010-06-18 |
joint signing clerk |
Dipl-Betriebsw. Björn
Komischke |
|
2010-06-18 |
2012-09-21 |
joint signing clerk |
Dr. Gerhard van der Meij |
|
2009-02-19 |
2010-07-29 |
chairman of the supervisory
board |
Dr. Horst Uwe Groh |
|
2010-07-29 |
2010-09-22 |
member of the supervisory
board |
Dr. Horst Uwe Groh |
|
1995-06-21 |
1997-05-16 |
deputy chairman of the
supervisory board |
Dr. Daniel Vasella |
|
Former shareholders: |
|||
|
From |
To |
Function |
Name |
|
|
1997-02-22 |
partner |
Sandoz Holding AG |
|
1997-02-22 |
2000-08-26 |
partner |
Novartis AG |
|
Former shareholdings: |
||
|
From |
To |
Name |
|
1996-05-08 |
1998-11-24 |
Novartis Handelsgesellschaft m.b.H. |
|
2004-09-16 |
2004-10-23 |
Novartis Forschungsinstitut GmbH |
|
2005-01-27 |
2005-10-06 |
Grandis Handel mit pharmazeutischen Produkten Gesellschaft
mbH |
|
2006-01-24 |
2007-11-10 |
Nabriva Therapeutics AG |
|
1996-12-03 |
2014-10-08 |
Novartis Animal Health GmbH |
|
1993-12-17 |
2014-05-09 |
Biozym GmbH in Liqu. |
|
Mergers: |
||
|
Date |
Function |
Name |
|
2014-10-08 |
merged with |
Novartis Animal Health GmbH |
|
2006-12-14 |
merged with |
Sandoz GmbH |
|
2005-10-06 |
merged with |
Grandis Handel mit pharmazeutischen Produkten Gesellschaft
mbH |
|
2000-11-24 |
merged with |
Novartis Handelsgesellschaft m.b.H. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.88 |
|
|
1 |
Rs.96.90 |
|
Euro |
1 |
Rs.76.29 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.